Europe beta glucan market has its primary application in food & beverages sector, pharmaceutical sector, animal feed and the personal care sector. As a result, the market is expected to rise with a CAGR of 7.10% over the forecast period of 2019-2027. European markets belonging to the UK, Germany, Spain, Italy, France and the Rest of Europe are covered in this report.
The Europe beta glucan market is driven by the rising personal care and cosmetic industry coupled with growing diseases such as coronary heart diseases cancer and diabetes coupled with food approvals by food authorities to increasing applications in pharmaceutical sector, food and beverage sector and personal sector. High demand for packaged foods and increasing prevalence of packaged foods are driving the beta-glucan market demand in the UK. The France beta glucan market is expanding due to increasing demand from the pharmaceutical sector while the German market is being propelled by its cosmetics and personal care sector. The growing prevalence of cancer in the overall European market too is playing a critical factor in enhancing the market demand. According to European Commission, Cancer had been the leading cause of death in European Union over the last decade (2007-2017). Beta-glucan can be used intravenously to treat various forms of cancers and boost the immune system of individuals.
Major market players like Garuda International Inc., Millipore Sigma, Ceapro Inc., Kerry Group PLC, Tate and Kyle PLC, Super Beta Glucan Inc., Cargill Incorporated, Immunomedic AS, Kemin Industries, Lesaffre Human Care, DSM NV, and Biotech PharmaCon ASA are competing in this market.